Search
Valganciclovir
go.drugbank.com/drugs/DB01610ApprovedInvestigationalAs the L-valyl ester of ganciclovir, it is actually a prodrug for ganciclovir. After oral administration, it is rapidly converted to ganciclovir by intestinal and hepatic esterases. … Valganciclovir hydrochloride (Valcyte, manufactured by Roche) is an antiviral medication used to treat cytomegalovirus infections.
Categories: Heterocyclic Compounds, 2-RingProducts: AVALCEPT 50 MG / ML ORAL ÇÖZELTİ HAZIRLAMAK İÇİN TOZ, 100 ML, RUNAVIR®450 MGFluvoxamine
go.drugbank.com/drugs/DB00176ApprovedInvestigationalFluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. … As of the end of 1995, more than 10 million patients worldwide have been treated with fluvoxamine.
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesProducts: VERLIN TABLETAS X 50 MG, FAVERIN 100 MGAtosiban
go.drugbank.com/drugs/DB09059ApprovedInvestigationalAlthough initial studies suggested it could be used as a nasal spray and hence would not require hospital admission, it is not used in that form. … Atosiban is an inhibitor of the hormones oxytocin and vasopressin. It is used intravenously to halt premature labor.
Products: Atosiban EVER Pharma 75 mg/10 ml Konzentrat zur Herstellung einer Infusionslösung, EVERPREM® SOLUCIÓN PARA INFUSIÓN 6.75 MG/0.9 MLExenatide
go.drugbank.com/drugs/DB01276ApprovedInvestigationalExenatide is a glucagon-like peptide-1 (GLP-1) analog[L42690]. … Exenatide was given FDA approval on April 28, 2005[L6106]. It is available as immediate- and extended-release formulations.
Synonyms: Exendin 4, Exendin-4Categories: Glucagon-like peptide-1 (GLP-1) analogues, GLP-1 AgonistsArtesunate
go.drugbank.com/drugs/DB09274ApprovedInvestigational[L890] Artesunate was developed out of a need for a more hydrophilic derivative of [artemisinin].[A203948] Artesunate was granted FDA approval on 26 May 2020.[L14099] … [L14099] The World Health Organization recommends artesunate as first line treatment for severe malaria.
Mixtures: อาร์ทีซูเนทและเมฟลอควินไฮโดรคลอไรด์ 100/220 มก.Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesRWJ-800088
go.drugbank.com/drugs/DB18693InvestigationalRWJ-800088 is a synthetic PEGylated thrombopoietin (TPO) mimetic (TPOm) peptide with no sequence homology to endogenous TPO.
Synonyms: a synthetic PEGylated thrombopoietin (TPO) mimetic (TPOm) peptide with no sequence homology to endogenous, -GLUTAMYLGLYCYL-L-PROLYL-L-THREONYL-L-LEUCYL-L-ARGINYL-L-GLUTAMINYL-3-(2-NAPHTHALENYL)-L-ALANYL-L-LEUCYL-L-ALANYL-L-ALANYDigoxin
go.drugbank.com/drugs/DB00390ApprovedInvestigational[A178234] Digoxin is classified as a cardiac glycoside and was initially approved by the FDA in 1954. … [A178225] It is a common agent used to manage atrial fibrillation and the symptoms of heart failure.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, BSEP/ABCB11 Substrates with a Narrow Therapeutic IndexInternational brands: Digocard-GNeuropeptide Y receptor type 2
go.drugbank.com/bio_entities/BE0002419TargetHumansReceptor for neuropeptide Y (NPY) and peptide YY (PYY) (PubMed:7592910, PubMed:7559383, PubMed:35507650, PubMed:36525977, PubMed:38882210).
Polypeptides: Neuropeptide Y receptor type 2Lorlatinib
go.drugbank.com/drugs/DB12130ApprovedInvestigationalinclude lorlatinib as a first-line treatment option in advanced ALK-positive NSCLC. … Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer[L39905] which was first approved by the US FDA in November of 2018
Categories: MATE 1 Inhibitors, P-glycoprotein inducersProducts: LORBRENA® 100 MG, LORVIQUA (TABLETS 100 MG)Candesartan cilexetil
go.drugbank.com/drugs/DB00796ApprovedInvestigationalCandesartan lowers blood pressure by antagonizing the renin-angiotensin-aldosterone system (RAAS); it competes with angiotensin II for binding to the type-1 angiotensin II receptor (AT1) subtype and prevents … It may also be used as an alternative agent for the treatment of heart failure, systolic dysfunction, myocardial infarction and coronary artery disease.
Mixtures: Candesartan/Amlodipin 1A Pharma 8 mg/10 mg – Hartkapseln, Candesartan/Amlodipin 1A Pharma 16 mg/10 mg – HartkapselnCategories: Angiotensin 2 Receptor Blocker, P-glycoprotein inhibitors